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Section A 
Multiple Choice Questions 
Total No. of Marks for this Section: 20 
 
The answers for this section should be written on the 100-MCQ Answer Sheet provided.  Please 
ensure that your name and student number have been written on the answer sheet. 
Answer ALL (40) questions 
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Section B 
Extended-Answer Questions 
Total No. of Marks for this Section: 80 
 
This section should be answered in the 20-page Answer Booklet provided. 
Answer any EIGHT (8) questions. 
 






These following agents have been used as antiplatelets.  Briefly describe their mechanisms of 
action: 











(a) Draw a diagram of plasma concentration versus time curves showing the difference 
between administration by intravenous bolus injection (A) and by oral route (B).  Use 
this diagram to describe how bioavailability is determined. 
 (5 marks) 
(b) Define plasma half-life.  Explain how this pharmacokinetic parameter can be 
influenced by plasma protein binding, clearance and the apparent volume of 
distribution of a drug? 
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Question 3 (multiple topics) 
(a) What is meant by the term ‘pH-dependence’ with respect to local anaesthetics? 
 (5 marks) 
(b) Acetylcholine-stimulated relaxation of resistance vessels is dependent on the presence 
of intact endothelial cells.  Describe in detail the steps that are involved in this vaso-
relaxation.  






(a) Describe the mechanism by which digoxin affects myocardial contractility. 
 (4 marks) 
(b) What would be the expected effects on the following parameters when a patient with 
congestive heart failure is treated with digoxin?  Include in your answer a brief 
explanation of how they occur. 
(i) Heart rate (2 marks) 
(ii) End diastolic volume (2 marks) 






(a) Name ONE (1) major therapeutic indication for drugs which inhibit angiotensin 
converting enzyme (ACE) and describe in detail how they produce their therapeutic 
effect. 
 (4 marks) 
(b) What toxicity can arise when an ACE inhibitor is used together with naproxen (a non-
steroidal anti-inflammatory agent)?  Explain in detail the mechanisms leading to this 
toxicity. 
 (6 marks) 
  
THIS EXAMINATION PAPER AND SUPPLIED MATERIALS ARE NOT PERMITTED TO BE REMOVED FROM 
ANY EXAMINATION VENUE IN ANY CIRCUMSTANCE 
 
Semester 1, 2015 FINAL EXAMINATION 
 PHA210 – Pharmacology 1 
Page 5 of 17 
 
Question 6 (multiple topics) 
Mr SM has a medical history of hard to control hypertension.  His medications include these 
following agents.  Describe in detail their mechanisms of action and explain how they benefit 
Mr SM. 
(a) Atorvastatin (4 marks) 
(b) Hydrochlorothiazide (2 marks) 
(c) Candesartan (2 marks) 






(a) Compare the mechanisms of ranitidine and esomeprazole in reducing gastric acidity.  
Which is the more effective?  Explain your answer. 
 (7 marks) 
(b) ‘Triple therapy’ is sometimes required for the treatment of peptic ulcers.  Explain what 
‘triple therapy’ is and when this type of treatment is necessary. 






Ms PK has been diagnosed with atrial fibrillation so her doctor initiates warfarin therapy.  
For the first 7 days, her doctor also asks her to inject herself with enoxaparin, a low 
molecular weight heparin (LMWH). 
(a) Briefly describe the mechanisms of action of enoxaparin and warfarin. 
 (5 marks) 
(b) Explain why it is necessary to co-administer warfarin and enoxaparin when initiating 
the warfarin therapy. 
 (3 marks) 
(c) What are the antidotes for warfarin overdose?  Explain how they work. 
 (2 marks) 
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Question 9 (multiple topics) 
(a) Briefly discuss the mechanisms of action of amiodarone and the problem encountered 
with its clinical administration.  Indicate how this could be avoided. 
 (5 marks) 
(b) Are there any differences amongst the calcium-channel blocking agents?  Explain your 
answer and give examples. 





Question 10  
(a) Describe how glyceryl trinitrate (GTN) is of benefit in treating angina pectoris.  Include 
in your answer the mechanism of action of this agent. 
 (6 marks) 
(b) Name a class of drugs that can be usefully combined with GTN for the management of 
angina, and explain why they are useful. 
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